Description

TENOFOSHIV EM TAB (1X30)

Indications

Tenofoshiv EM Tab is primarily indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients aged 12 years and older. It is also used in the management of human immunodeficiency virus (HIV) infection as part of a combination antiretroviral therapy regimen. The medication is effective in reducing viral load and improving immune function, thus playing a crucial role in the long-term management of these chronic viral infections.

Mechanism of Action

Tenofoshiv, a nucleotide analog, functions by inhibiting the reverse transcriptase enzyme, which is essential for the replication of both HBV and HIV. By incorporating itself into the viral DNA, Tenofoshiv causes chain termination, preventing the synthesis of viral genomes. This action effectively reduces the viral load in the body, allowing the immune system to recover and combat the viral infections more effectively.

Pharmacological Properties

Tenofoshiv is characterized by its high potency against HBV and HIV. It has a favorable pharmacokinetic profile, with a long half-life that allows for once-daily dosing. The drug is well absorbed when taken orally, with peak plasma concentrations achieved within a few hours. It is primarily excreted through the kidneys, necessitating dose adjustments in patients with renal impairment. The drug’s stability and efficacy make it a preferred choice in antiviral therapy.

Contraindications

Tenofoshiv EM Tab is contraindicated in patients with a known hypersensitivity to Tenofoshiv or any of the excipients in the formulation. Additionally, it should not be used in individuals with severe renal impairment (eGFR < 30 mL/min) without appropriate dosage adjustments and monitoring. Caution is advised in patients with a history of bone disorders or those at risk for renal toxicity.

Side Effects

Common side effects associated with Tenofoshiv EM Tab include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Other potential side effects may include headache, fatigue, and dizziness. More serious adverse effects, though less common, can include renal impairment, lactic acidosis, and hepatotoxicity. Regular monitoring of renal function and liver enzymes is recommended during treatment to mitigate these risks.

Dosage and Administration

The recommended dosage of Tenofoshiv EM Tab for adults and pediatric patients weighing at least 35 kg is one tablet (300 mg) taken orally once daily, with or without food. For patients with renal impairment, dosage adjustments may be necessary based on the estimated glomerular filtration rate (eGFR). It is essential to adhere to the prescribed regimen and not to discontinue the medication abruptly without consulting a healthcare provider, as this may lead to viral rebound and resistance.

Interactions

Tenofoshiv EM Tab may interact with other medications, potentially affecting their efficacy or increasing the risk of adverse effects. Notably, co-administration with nephrotoxic agents or other antiviral medications should be approached with caution. It is crucial for healthcare providers to review a patient’s complete medication list to identify potential drug-drug interactions. Patients should be advised to inform their healthcare provider of all medications, supplements, and herbal products they are taking.

Precautions

Before initiating treatment with Tenofoshiv EM Tab, a thorough assessment of the patient’s medical history is essential. Special precautions should be taken in patients with pre-existing renal impairment, as the drug is primarily excreted via the kidneys. Regular monitoring of renal function is recommended throughout the treatment course. Additionally, patients should be monitored for signs of lactic acidosis and hepatotoxicity, especially if they have underlying liver disease or are receiving concomitant medications that may exacerbate these conditions.

Clinical Studies

Clinical studies have demonstrated the efficacy of Tenofoshiv EM Tab in reducing HBV viral load and improving liver function parameters. In randomized controlled trials, patients treated with Tenofoshiv showed significant reductions in HBV DNA levels compared to those receiving placebo. Furthermore, studies involving HIV-infected patients have indicated that Tenofoshiv, when used in combination with other antiretroviral agents, leads to improved virologic outcomes and better tolerability profiles. Ongoing research continues to evaluate the long-term effects and safety of Tenofoshiv in diverse patient populations.

Conclusion

Tenofoshiv EM Tab represents a significant advancement in the treatment of chronic hepatitis B and HIV infections. Its potent antiviral activity, favorable pharmacokinetic properties, and once-daily dosing regimen make it a valuable option in the management of these chronic conditions. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to optimize patient outcomes. Regular monitoring and patient education are critical components of successful therapy with Tenofoshiv.